US CFTC investigates staff suspected of using insider information from Trump speech for prediction event trading
Odaily reported that the U.S. Commodity Futures Trading Commission (CFTC) is investigating a potential insider trading incident involving the prediction market platform Kalshi. An individual reportedly responsible for operating former President Trump's teleprompter is accused of placing bets on related prediction event contracts.
According to reports, this person may have used advance access to the content of Trump's public speeches to bet on whether specific statements would be released or include certain phrases on the Kalshi platform. Currently, the CFTC is investigating whether these trades involved the use of non-public information and if they violated prediction market trading rules.
This investigation has once again raised market concerns about the risks of insider trading in prediction markets. As platforms like Kalshi and Polymarket see rapid growth in trading volume, prediction contracts involving political, economic, and public events are increasingly drawing the attention of regulators. (CNBC)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Variational open interest has exceeded $2 billions.
Janus Henderson Macro Head Says Market Is Near Its Top but Cannot Say When
A $5.7 billion patent verdict has been issued, Burford Capital (BUR.US) may receive $1.4 billion, and its share price soared by more than 12%.
Burford Capital Ltd. surged more than 12% on Monday, marking its largest intraday increase since the end of March, after a federal jury delivered a verdict in a patent case involving Apple.
Pfizer (PFE.US), BioNTech (BNTX.US), and Moderna (MRNA.US) seek dismissal of Bayer’s Monsanto mRNA patent lawsuit, but the judge rejects the request
A federal judge in Delaware on Monday rejected the requests from Pfizer, BioNTech, and Moderna to dismiss a lawsuit filed against them by Monsanto, a subsidiary of the German pharmaceutical giant Bayer. The lawsuit concerns these pharmaceutical companies' use of a patent related to mRNA technology.
